An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

Detalles Bibliográficos
Autores principales: Talreja, Vikas T., Noronha, Vanita, Joshi, Amit, Patil, Vijay, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956583/
https://www.ncbi.nlm.nih.gov/pubmed/31956609
http://dx.doi.org/10.4103/sajc.sajc_157_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956583/
https://www.ncbi.nlm.nih.gov/pubmed/31956609
http://dx.doi.org/10.4103/sajc.sajc_157_19

Ejemplares similares